Business Context and Reporting Period
Company: Nektar Therapeutics (NKTR)
Filing Type: Form 8-K (Current Report)
Date of Report: September 18, 2025
Reporting Period: Event-based report regarding clinical trial updates.
Key Financial Metrics
This filing is a Current Report on Form 8-K and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on regulatory disclosures and clinical trial events.
Material Changes and Events
- Item 7.01 (Regulation FD Disclosure): Nektar posted slides on its website containing additional information regarding new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin.
- Item 8.01 (Other Events): The company announced new data from the REZOLVE-AD Phase 2b study of rezpegaldesleukin for the treatment of atopic dermatitis.
- Event Context: The data was presented as a Late-Breaker Oral Presentation at EADV 2025.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release and presentation slides (Exhibits 99.1 and 99.2) detailing the efficacy and safety of rezpegaldesleukin. The text explicitly states that information on the company's website is not incorporated by reference into this report.
Forward-Looking Statements: Nektar undertakes no obligation to update, supplement, or amend the material attached as Exhibit 99.1.
Risks and Contingencies: No specific financial risks or contingencies are detailed in this filing text; the focus is on the clinical development status of the drug candidate.
Investor Verification Checklist
- Review Exhibit 99.1 (Slides) for specific efficacy and safety data from the 16-week induction of the REZOLVE-AD Phase 2b study.
- Review Exhibit 99.2 (Press Release) for the full context of the EADV 2025 presentation.
- Verify the status of the REZOLVE-AD Phase 2b study and any implications for future regulatory filings or Phase 3 development.
- Confirm that website content referenced in the filing is not legally part of this 8-K submission.